Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2017 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
August 07, 2017 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
August 02, 2017 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
June 14, 2017 07:00 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
June 07, 2017 06:45 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
June 05, 2017 06:45 ET | Source: Calithera Biosciences, Inc.

CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
May 10, 2017 06:59 ET | Source: Calithera Biosciences, Inc.

Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma

Study to evaluate potential of CB-839 plus Opdivo to target immunosuppressive cancer metabolism in the tumor microenvironmentCompanies have ongoing collaboration evaluating clear cell renal cell...
May 09, 2017 16:06 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights

-Strong quarter-end cash position of $207.1 million supports advancement of multiple clinical development programs-Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern...
May 03, 2017 07:30 ET | Source: Calithera Biosciences, Inc.

Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

SOUTH SAN FRANCISCO, Calif., May 03, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
April 20, 2017 10:32 ET | Source: Calithera Biosciences, Inc.

CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...